Skip to content

Head to head

BPC-157 against Thymosin Beta-4

The two healing peptides with the largest preclinical literatures, and the comparison people mean when they say BPC-157 against TB-500. Thymosin beta-4 is the real 43 residue peptide with investigational trials in eye conditions, not the fragment sold under the research name.

Column A

BPC-157

Body Protection Compound 157

A pentadecapeptide with a large animal literature on tendon, ligament, muscle and gut healing, and a small human record: two rectal-enema studies run in Croatia, three uncontrolled clinic reports, and a randomized Phase 2 injury trial now recruiting.

Column B

Thymosin Beta-4

Thymosin Beta-4 (TB4)

A naturally occurring actin-binding peptide studied for wound healing, cardiac repair, and eye conditions; the parent molecule of TB-500.

Side by side, on the facts we can check

AttributeBPC-157Thymosin Beta-4
CategoryHealing & RecoveryHealing & Recovery
FDA statusNot FDA-approved. Removed from Category 2 (April 2026); PCAC voted 8 to 6, one abstention, to recommend for compounding (July 2026) against the FDA reviewers' recommendation; awaiting FDA actionNot FDA-approved; investigational (clinical trials for eye conditions)
Half-lifeUnder 30 minutes in plasma in a two-person pilot; the animal literature describes effects lasting hours to days.~2 hours
Molecular weight1,419.5 Da4,963.4 Da
MechanismIn animal work BPC-157 promotes angiogenesis, interacts with the nitric oxide system, and raises growth hormone receptor expression and growth factor signaling in tendon fibroblasts. No receptor or molecular target has been identified, which FDA's 2026 evaluation gave as one reason it could not judge biological plausibility. Human mechanistic work is limited to the observation that the peptide was not detectable in plasma after rectal dosing, and to a two-person pilot consistent with a plasma half-life under 30 minutes, against effects that animal studies describe as lasting hours to days.Binds actin to regulate the cytoskeleton, promoting cell migration, angiogenesis, and reduced inflammation at injury sites.
Human studies cited52
Legal status, USNot approved; research use onlyNot approved; research use only
open the BPC-157 profileopen the Thymosin Beta-4 profile

Frequently asked questions

What is the difference between BPC-157 and Thymosin Beta-4?

BPC-157: A pentadecapeptide with a large animal literature on tendon, ligament, muscle and gut healing, and a small human record: two rectal-enema studies run in Croatia, three uncontrolled clinic reports, and a randomized Phase 2 injury trial now recruiting. Thymosin Beta-4: A naturally occurring actin-binding peptide studied for wound healing, cardiac repair, and eye conditions; the parent molecule of TB-500.

Which has stronger research evidence, BPC-157 or Thymosin Beta-4?

This database does not grade compounds. It counts what was run in people: 5 of the 12 studies cited on the BPC-157 profile were human work, against 2 of 4 for Thymosin Beta-4. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.

Are BPC-157 and Thymosin Beta-4 FDA-approved?

BPC-157: Not FDA-approved. Removed from Category 2 (April 2026); PCAC voted 8 to 6, one abstention, to recommend for compounding (July 2026) against the FDA reviewers' recommendation; awaiting FDA action. Thymosin Beta-4: Not FDA-approved; investigational (clinical trials for eye conditions).

Related posts

Blog articles that cover BPC-157 or Thymosin Beta-4, newest first.

Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.